Obesity
Conditions
Interventions
This is a randomized, not blinded, controlled clinical trial with two parallel groups. A total of 36 men with hypogonadism, overweight, or obesity, defined by a body mass index between 25 and 35 kilog
Sponsors
Hospital e Maternidade São Domingos
Hospital e Maternidade São Domingos
Eligibility
Sex/Gender
Male
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Obese or overweight men (Body Mass Index above 25 and less than 35; between 30 and 60 years of age; with low testosterone levels (less than 350 nanograms per deciliter); with symptoms of hypogonadism
Exclusion criteria
Exclusion criteria: Individuals interested in fertility in the 6 months following therapy; presence of Diabetes Mellitus; presence of hypertension; presence of Nephropathy; presence of heart disease; presence of Hepatopathy; presence of Depression; presence of anxiety disorders; presence of other hormonal diseases; presence of Hypogonadism of primary cause (testicular failure); diagnosis of active prostate or breast cancer; previous diagnosis of breast cancer; severe urinary symptoms through the score; International Prostate Symptom Score greater than 19; severe cardiopulmonary disease such as unstable angina and recent myocardial infarction; personal or family history of Thromboembolism; hematocrit above 48 percent; patients with implanted medical devices (pacemakers) or essential support devices such as monitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A significant impact of testosterone replacement therapy on weight loss and muscle mass is expected | — |
Secondary
| Measure | Time frame |
|---|---|
| A significant impact of testosterone replacement therapy on quality of life and sexual health scores is expected;A significant impact of testosterone replacement therapy on metabolic and inflammatory parameters is expected | — |
Countries
Brazil
Contacts
Public ContactRodrigo Diniz
Universidade Federal do Maranhão
Outcome results
None listed